According to a recent LinkedIn post from C Ray Therapeutics, the company has obtained AAALAC International Full Accreditation for its animal care program. The post positions this as validation of its laboratory animal welfare and research-ethics standards for preclinical work conducted in China.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights that its integrated facility combines AAALAC-accredited animal care with cGMP manufacturing under China’s Class A Radiation Safety License. It also notes support for more than 30 radioisotopes, including Ac-225, and experience across over 70 projects, 16 investigator-initiated trials, and 2 programs that have reached Phase III.
For investors, the accreditation and described capabilities suggest C Ray Therapeutics is aiming to strengthen its appeal as a radiopharmaceutical CRDMO partner for global sponsors seeking preclinical and early clinical work in China. The emphasis on ethics, regulatory compliance, and late-stage project experience could enhance the company’s competitive position and support higher-value contract opportunities.
The post also points to the firm’s business development efforts, mentioning participation by its senior BD executive in a TRP Summit 2026 panel on preclinical strategy for Phase Zero or first-in-human trials. This visibility within a specialized industry forum may help expand its network among drug developers and could contribute to future deal flow and pipeline growth.